trending Market Intelligence /marketintelligence/en/news-insights/trending/tl9XGCrCtlRUxHf3kjDCbA2 content esgSubNav
In This List

JobLocationMap Q1 loss narrows YOY

Video

S&P Capital IQ Pro | Powering Your Edge

Case Study

A Prestigious Global Business School Gains a Competitive Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Gaining a Competitive Advantage with ESG Data for Student-Managed Investment Funds


JobLocationMap Q1 loss narrows YOY

Bioscience Neutraceuticals Inc. said its first-quarter normalized net income was a loss of $2,180, compared with a loss of $2,320 in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

Reported net income totaled a loss of $3,500, or a loss of 0 cents per share, compared to a loss of $3,710, or a loss of 0 cents per share, in the year-earlier period.